HK Stock Market Move | Innovative drug concept stocks continue to rise. Three significant BD deals for innovative drugs have been finalized in a single day. The industry is gradually entering a stage of value realization.

Innovative pharmaceutical concept stocks continue their upward trend. As of the time of this report, ZAI LAB (09688) is up by 6.35%, trading at HKD 20.98; CSPC PHARMA (01093) is up by 5.71%, trading at HKD 9.17; GENSCRIPT BIO (01548) is up by 5.55%, trading at HKD 26.4; and HANSOH PHARMA (03692) is up by 4.78%, trading at HKD 35.1. In terms of news, the authorization of innovative drugs going overseas has entered a high-frequency phase, with three significant transactions occurring on August 10: BeOne Medicines Ltd. partnered with Revolution Medicines to explore innovative combination treatment options for tumors and secured exclusive development and commercialization rights for four clinical-stage candidates in certain Asian markets; INNOVENT BIO teamed up with Daiichi Sankyo to obtain the commercialization rights for VERSATIS in mainland China; Gan & Lee Pharmaceuticals is leveraging Menarini to advance its self-developed GLP-1 innovative drug into the European market. Zhongtai points out that since 2026, China's innovative drug industry has gradually entered a value realization phase. The industry's logic has shifted from relying on business development (BD) events to international commercialization, clinical data realization, and sustained revenue contribution. Recent financial reports from leading overseas pharmaceutical companies continue to validate the value of Chinese innovative assets, and multinational corporations (MNCs) are gradually enhancing their strategic positioning for Chinese innovative drugs.